Drug developed using DRDO technology gets DCGI approval

Category : Science and Tech Published on: March 18 2023

Share on facebook

A critical drug, 'prussian blue' insoluble formulations developed on a Defence Research and Development Organisation (DRDO) technology recently received approval from the Drugs Controller General of India (DCGI).
It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies.
It was developed under the Technology Development Fund (TDF).
The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
The formulations are used for the decontamination of Cesium and Thallium.
The drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.